Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Myriad Genetics Inc (MYGN)

Myriad Genetics Inc (MYGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MYGN Stock Might Gain From the New Recognition of RiskScore Study
MYGN Stock Might Gain From the New Recognition of RiskScore Study Zacks Investment Research - Fri Dec 20, 8:10AM CST

Myriad Genetics, Inc.’s MYGN MyRisk Hereditary Cancer Test with RiskScore study has been named as one of its top 10 significant advances in genomic medicine by the American Journal of Human Genetics....

MYGN : 13.36 (+1.44%)
PEN : 242.54 (-0.40%)
PAHC : 21.69 (-0.55%)
HAE : 75.44 (-1.90%)
Myriad Genetics' MyRisk® Hereditary Cancer Test with RiskScore® Recognized as Top Advance in Genomic Medicine Quiver Quantitative, Inc. - Fri Dec 20, 1:24AM CST

Myriad Genetics' MyRisk® Hereditary Cancer Test with RiskScore® was recognized as a significant advance in genomic medicine.Quiver AI SummaryMyriad Genetics, Inc. announced that its MyRisk® Hereditary...

MYGN : 13.36 (+1.44%)
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics GlobeNewswire - Thu Dec 19, 3:15PM CST

MYGN : 13.36 (+1.44%)
Myriad Genetics Engages with UnitedHealthcare on Access to GeneSight Test Following Policy Update Quiver Quantitative, Inc. - Wed Dec 11, 3:46AM CST

Myriad Genetics updates on discussions with UnitedHealthcare regarding access to GeneSight test following policy changes effective January 2025.Quiver AI SummaryMyriad Genetics, Inc. has provided an update...

MYGN : 13.36 (+1.44%)
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing GlobeNewswire - Tue Dec 10, 5:26PM CST

MYGN : 13.36 (+1.44%)
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member GlobeNewswire - Tue Dec 10, 3:05PM CST

MYGN : 13.36 (+1.44%)
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain?
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain? Zacks Investment Research - Tue Dec 10, 7:14AM CST

Myriad Genetics, Inc.’s MYGN Prolaris prostate cancer prognostic test has been reinforced as an ‘Advanced Tool’ by the National Comprehensive Cancer Network (“NCCN”) in the fight against prostate...

MYGN : 13.36 (+1.44%)
PEN : 242.54 (-0.40%)
PAHC : 21.69 (-0.55%)
HAE : 75.44 (-1.90%)
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines GlobeNewswire - Tue Dec 10, 7:00AM CST

MYGN : 13.36 (+1.44%)
Myriad Genetics to Present New Breast Cancer Risk Assessment Data at 2024 San Antonio Breast Cancer Symposium Quiver Quantitative, Inc. - Tue Dec 10, 1:22AM CST

Myriad Genetics will present new breast cancer risk assessment data and MRD assay findings at the 2024 SABCS.Quiver AI SummaryMyriad Genetics, Inc. announced that it will present new research at the 2024...

MYGN : 13.36 (+1.44%)
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium GlobeNewswire - Mon Dec 9, 3:05PM CST

MYGN : 13.36 (+1.44%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot